Limits...
Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues.

Sysel AM, Valli VE, Bauer JA - Oncotarget (2015)

Bottom Line: This study quantified the immunohistochemical expression of the cobalamin transport protein (transcobalamin II; TCII), cell surface receptor (transcobalamin II-R; TCII-R) and proliferation protein (Ki-67) in naturally occurring canine and feline malignant tumors, and compared these results to expression in corresponding adjacent normal tissues.Expression of TCII, TCII-R and Ki-67 was significantly higher in malignant tumor tissues than in corresponding adjacent normal tissues in both species.These results demonstrate a quantifiable, synchronous up-regulation of TCII and TCII-R expression by proliferating canine and feline malignant tumors.

View Article: PubMed Central - PubMed

Affiliation: Bauer Research Foundation, Akron, Ohio, USA.

ABSTRACT
Cancer cells have an obligate need for cobalamin (vitamin B12) to enable DNA synthesis necessary for cellular replication. This study quantified the immunohistochemical expression of the cobalamin transport protein (transcobalamin II; TCII), cell surface receptor (transcobalamin II-R; TCII-R) and proliferation protein (Ki-67) in naturally occurring canine and feline malignant tumors, and compared these results to expression in corresponding adjacent normal tissues. All malignant tumor tissues stained positively for TCII, TCII-R and Ki-67 proteins; expression varied both within and between tumor types. Expression of TCII, TCII-R and Ki-67 was significantly higher in malignant tumor tissues than in corresponding adjacent normal tissues in both species. There was a strong correlation between TCII and TCII-R expression, and a modest correlation between TCII-R and Ki-67 expression in both species; a modest association between TCII and Ki-67 expression was present in canine tissues only. These results demonstrate a quantifiable, synchronous up-regulation of TCII and TCII-R expression by proliferating canine and feline malignant tumors. The potential to utilize these proteins as biomarkers to identify neoplastic tissues, streamline therapeutic options, evaluate response to anti-tumor therapy and monitor for recurrent disease has important implications in the advancement of cancer management for both human and companion animal patients.

Show MeSH

Related in: MedlinePlus

Graphical representation of TCII, TCII-R and Ki-67 expression in feline malignant tumor tissues and corresponding adjacent normal tissuesTissue samples were immunohistochemically stained for TCII (TCN2 antibody), TCII-R (CD320 antibody) and Ki-67 (MIB-1 antibody). TCII and TCII-R data are represented as mean +/− SEM. (A) TCII and TCII-R expression in feline malignant tumor tissues. (B) TCII and TCII-R expression in corresponding adjacent normal feline tissues. (C) Ki-67 expression in feline malignant tumor tissues. (D) Ki-67 expression in corresponding adjacent normal feline tissues. X-axis case identification includes: (1) biliary carcinoma 10021255, (2) biliary carcinoma 10101918, (3) biliary carcinoma 10121242, (4) dermal carcinoma 10071506, (5) dermal carcinoma 11030645, (6) dermal carcinoma 11111180, (7) fibrosarcoma - vaccine 10051260, (8) fibrosarcoma - vaccine 11120550, (9) fibrosarcoma - vaccine 9070268, (10) intestinal adenocarcinoma 11100237, (11) intestinal adenocarcinoma 11101952, (12) intestinal adenocarcinoma 11120080, (13) intestinal lymphoma 11101365, (14) intestinal lymphoma 10120094, (15) intestinal lymphoma 11120834, (16) intestinal mast cell tumor 11071015, (17) intestinal mast cell tumor 11080200, (18) intestinal mast cell tumor 11111192, (19) mammary adenocarcinoma 11051222, (20) mammary adenocarcinoma 11051232, (21) mammary adenocarcinoma 11071104, (22) nodal lymphoma 11111342, (23) nodal lymphoma 11111667, (24) nodal lymphoma 11112001, (25) oral squamous cell carcinoma 11110315, (26) oral squamous cell carcinoma 11120118, (27) oral squamous cell carcinoma 11120336, (28) sarcoma 11041581, (29) soft tissue sarcoma 11011745, (30) soft tissue sarcoma 11091746, (31) splenic mast cell tumor 11031700, (32) splenic mast cell tumor 11050011, (33) splenic mast cell tumor 11050097, (34) urinary bladder transitional cell carcinoma 10060321, (35) urinary bladder transitional cell carcinoma 11011306, (36) urinary bladder transitional cell carcinoma 11041886.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4385855&req=5

Figure 3: Graphical representation of TCII, TCII-R and Ki-67 expression in feline malignant tumor tissues and corresponding adjacent normal tissuesTissue samples were immunohistochemically stained for TCII (TCN2 antibody), TCII-R (CD320 antibody) and Ki-67 (MIB-1 antibody). TCII and TCII-R data are represented as mean +/− SEM. (A) TCII and TCII-R expression in feline malignant tumor tissues. (B) TCII and TCII-R expression in corresponding adjacent normal feline tissues. (C) Ki-67 expression in feline malignant tumor tissues. (D) Ki-67 expression in corresponding adjacent normal feline tissues. X-axis case identification includes: (1) biliary carcinoma 10021255, (2) biliary carcinoma 10101918, (3) biliary carcinoma 10121242, (4) dermal carcinoma 10071506, (5) dermal carcinoma 11030645, (6) dermal carcinoma 11111180, (7) fibrosarcoma - vaccine 10051260, (8) fibrosarcoma - vaccine 11120550, (9) fibrosarcoma - vaccine 9070268, (10) intestinal adenocarcinoma 11100237, (11) intestinal adenocarcinoma 11101952, (12) intestinal adenocarcinoma 11120080, (13) intestinal lymphoma 11101365, (14) intestinal lymphoma 10120094, (15) intestinal lymphoma 11120834, (16) intestinal mast cell tumor 11071015, (17) intestinal mast cell tumor 11080200, (18) intestinal mast cell tumor 11111192, (19) mammary adenocarcinoma 11051222, (20) mammary adenocarcinoma 11051232, (21) mammary adenocarcinoma 11071104, (22) nodal lymphoma 11111342, (23) nodal lymphoma 11111667, (24) nodal lymphoma 11112001, (25) oral squamous cell carcinoma 11110315, (26) oral squamous cell carcinoma 11120118, (27) oral squamous cell carcinoma 11120336, (28) sarcoma 11041581, (29) soft tissue sarcoma 11011745, (30) soft tissue sarcoma 11091746, (31) splenic mast cell tumor 11031700, (32) splenic mast cell tumor 11050011, (33) splenic mast cell tumor 11050097, (34) urinary bladder transitional cell carcinoma 10060321, (35) urinary bladder transitional cell carcinoma 11011306, (36) urinary bladder transitional cell carcinoma 11041886.

Mentions: Immunohistochemical staining values for feline tissues are summarized in Table 1 and illustrated graphically in Figure 3; digital images of all stained slides are shown in Figure 4.


Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues.

Sysel AM, Valli VE, Bauer JA - Oncotarget (2015)

Graphical representation of TCII, TCII-R and Ki-67 expression in feline malignant tumor tissues and corresponding adjacent normal tissuesTissue samples were immunohistochemically stained for TCII (TCN2 antibody), TCII-R (CD320 antibody) and Ki-67 (MIB-1 antibody). TCII and TCII-R data are represented as mean +/− SEM. (A) TCII and TCII-R expression in feline malignant tumor tissues. (B) TCII and TCII-R expression in corresponding adjacent normal feline tissues. (C) Ki-67 expression in feline malignant tumor tissues. (D) Ki-67 expression in corresponding adjacent normal feline tissues. X-axis case identification includes: (1) biliary carcinoma 10021255, (2) biliary carcinoma 10101918, (3) biliary carcinoma 10121242, (4) dermal carcinoma 10071506, (5) dermal carcinoma 11030645, (6) dermal carcinoma 11111180, (7) fibrosarcoma - vaccine 10051260, (8) fibrosarcoma - vaccine 11120550, (9) fibrosarcoma - vaccine 9070268, (10) intestinal adenocarcinoma 11100237, (11) intestinal adenocarcinoma 11101952, (12) intestinal adenocarcinoma 11120080, (13) intestinal lymphoma 11101365, (14) intestinal lymphoma 10120094, (15) intestinal lymphoma 11120834, (16) intestinal mast cell tumor 11071015, (17) intestinal mast cell tumor 11080200, (18) intestinal mast cell tumor 11111192, (19) mammary adenocarcinoma 11051222, (20) mammary adenocarcinoma 11051232, (21) mammary adenocarcinoma 11071104, (22) nodal lymphoma 11111342, (23) nodal lymphoma 11111667, (24) nodal lymphoma 11112001, (25) oral squamous cell carcinoma 11110315, (26) oral squamous cell carcinoma 11120118, (27) oral squamous cell carcinoma 11120336, (28) sarcoma 11041581, (29) soft tissue sarcoma 11011745, (30) soft tissue sarcoma 11091746, (31) splenic mast cell tumor 11031700, (32) splenic mast cell tumor 11050011, (33) splenic mast cell tumor 11050097, (34) urinary bladder transitional cell carcinoma 10060321, (35) urinary bladder transitional cell carcinoma 11011306, (36) urinary bladder transitional cell carcinoma 11041886.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4385855&req=5

Figure 3: Graphical representation of TCII, TCII-R and Ki-67 expression in feline malignant tumor tissues and corresponding adjacent normal tissuesTissue samples were immunohistochemically stained for TCII (TCN2 antibody), TCII-R (CD320 antibody) and Ki-67 (MIB-1 antibody). TCII and TCII-R data are represented as mean +/− SEM. (A) TCII and TCII-R expression in feline malignant tumor tissues. (B) TCII and TCII-R expression in corresponding adjacent normal feline tissues. (C) Ki-67 expression in feline malignant tumor tissues. (D) Ki-67 expression in corresponding adjacent normal feline tissues. X-axis case identification includes: (1) biliary carcinoma 10021255, (2) biliary carcinoma 10101918, (3) biliary carcinoma 10121242, (4) dermal carcinoma 10071506, (5) dermal carcinoma 11030645, (6) dermal carcinoma 11111180, (7) fibrosarcoma - vaccine 10051260, (8) fibrosarcoma - vaccine 11120550, (9) fibrosarcoma - vaccine 9070268, (10) intestinal adenocarcinoma 11100237, (11) intestinal adenocarcinoma 11101952, (12) intestinal adenocarcinoma 11120080, (13) intestinal lymphoma 11101365, (14) intestinal lymphoma 10120094, (15) intestinal lymphoma 11120834, (16) intestinal mast cell tumor 11071015, (17) intestinal mast cell tumor 11080200, (18) intestinal mast cell tumor 11111192, (19) mammary adenocarcinoma 11051222, (20) mammary adenocarcinoma 11051232, (21) mammary adenocarcinoma 11071104, (22) nodal lymphoma 11111342, (23) nodal lymphoma 11111667, (24) nodal lymphoma 11112001, (25) oral squamous cell carcinoma 11110315, (26) oral squamous cell carcinoma 11120118, (27) oral squamous cell carcinoma 11120336, (28) sarcoma 11041581, (29) soft tissue sarcoma 11011745, (30) soft tissue sarcoma 11091746, (31) splenic mast cell tumor 11031700, (32) splenic mast cell tumor 11050011, (33) splenic mast cell tumor 11050097, (34) urinary bladder transitional cell carcinoma 10060321, (35) urinary bladder transitional cell carcinoma 11011306, (36) urinary bladder transitional cell carcinoma 11041886.
Mentions: Immunohistochemical staining values for feline tissues are summarized in Table 1 and illustrated graphically in Figure 3; digital images of all stained slides are shown in Figure 4.

Bottom Line: This study quantified the immunohistochemical expression of the cobalamin transport protein (transcobalamin II; TCII), cell surface receptor (transcobalamin II-R; TCII-R) and proliferation protein (Ki-67) in naturally occurring canine and feline malignant tumors, and compared these results to expression in corresponding adjacent normal tissues.Expression of TCII, TCII-R and Ki-67 was significantly higher in malignant tumor tissues than in corresponding adjacent normal tissues in both species.These results demonstrate a quantifiable, synchronous up-regulation of TCII and TCII-R expression by proliferating canine and feline malignant tumors.

View Article: PubMed Central - PubMed

Affiliation: Bauer Research Foundation, Akron, Ohio, USA.

ABSTRACT
Cancer cells have an obligate need for cobalamin (vitamin B12) to enable DNA synthesis necessary for cellular replication. This study quantified the immunohistochemical expression of the cobalamin transport protein (transcobalamin II; TCII), cell surface receptor (transcobalamin II-R; TCII-R) and proliferation protein (Ki-67) in naturally occurring canine and feline malignant tumors, and compared these results to expression in corresponding adjacent normal tissues. All malignant tumor tissues stained positively for TCII, TCII-R and Ki-67 proteins; expression varied both within and between tumor types. Expression of TCII, TCII-R and Ki-67 was significantly higher in malignant tumor tissues than in corresponding adjacent normal tissues in both species. There was a strong correlation between TCII and TCII-R expression, and a modest correlation between TCII-R and Ki-67 expression in both species; a modest association between TCII and Ki-67 expression was present in canine tissues only. These results demonstrate a quantifiable, synchronous up-regulation of TCII and TCII-R expression by proliferating canine and feline malignant tumors. The potential to utilize these proteins as biomarkers to identify neoplastic tissues, streamline therapeutic options, evaluate response to anti-tumor therapy and monitor for recurrent disease has important implications in the advancement of cancer management for both human and companion animal patients.

Show MeSH
Related in: MedlinePlus